ASPIDOSPERMINE

An indole alkaloid having the structure of aspirospermidine methoxylated at C-17 and acetylated at N-1.


Midgut Neuroendocrine Tumor G1

category: biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

description: A neuroendocrine tumor grade 1 that arises from the jejunum, ileum, proximal colon, or appendix.


name: Metastatic Midgut Neuroendocrine Tumor G1

description: A midgut neuroendocrine tumor G1 that has spread from its original site of growth to another anatomic site.


A methyl-branched fatty acyl-CoA obtained from the formal condensation of the thiol group of coenzyme A with the carboxy group of (E)-isoheptadec-2-enoic acid.


Fetal Position above Umbilicus

category: biolink:PhenotypicFeature biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

description: A reference point for the fetal position when the fetal heart rate is detected above the mother's umbilicus.


name: Locally Advanced Digestive System Neuroendocrine Tumor G3

description: Digestive system neuroendocrine tumor G3 that has spread from its original site of growth to nearby tissues or lymph nodes.


A secondary amino compound that is spermidine in which each of the primary amino groups has been mono-acylated by formal condensation with trans-sinapic acid.


name: Psoralen and long-wave ultraviolet radiation (PUVA) keratosis

description: A hyperkeratotic skin lesion that occurs in patients with a history of prolonged exposure to psoralen and ultraviolet A (PUVA) therapy.


6-hydroxyferulic acid derivative

6-hydroxyferulic acid derivative


polonium-210 atom

The radioactive isotope of polonium with relative atomic mass 209.98286 and half-life of 138.376 days; the only naturally occurring isotope of polonium.


A branched trisaccharide that is alpha-L-Fucp-(1->3)-alpha-D-Galp in which the hydroxy group at position 4 of the D-galactopyranose moiety has been glycosylated by an alpha-D-glucopyranosyl group.


A medium-chain primary fatty alcohol that is dodecane carrying hydroxy groups at positions 1 and 11.


name: Grade 5 Intestinal Stoma Obstruction, CTCAE

description: Death


name: Grade 3 Skin Infection with Normal Absolute Neutrophil Count or Grade 1 or 2 Neutrophils, CTCAE


An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of cis-dec-4-enoic acid.


Ro 48-8071 fumarate

A fumarate salt obtained by combining Ro 48-8071 with one molar equivalent of fumaric acid. An inhibitor of lanosterol synthase.


tungsten disulfide nanotube

A nanotube consisting of tungsten disulfide.


L-mannitol

The L-enantiomer of mannitol.


name: Kidney Cancer Clinical Distant Metastasis TNM Finding v7

description: A clinical finding about one or more characteristics of kidney cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.


Kidney Cancer cM0 TNM Finding v7

description: Kidney cancer without evidence of distant metastasis. (from AJCC 7th Ed.)


Kidney Cancer cM1 TNM Finding v7

description: Kidney cancer with distant metastasis. (from AJCC 7th Ed.)


A methyl-branched fatty acyl-CoA obtained from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-hydroxyisopentadecanoic acid.


Oral Cavity Mucosal Melanoma

description: A rare melanoma that arises from the oral cavity. It is associated with a poor prognosis.


A member of the class of piperidines that is TEMPO carrying a methacryloyloxy group at position 4.


aplysiatoxins

A class of macrodiolides that consists of aplysiatoxin and its structural analogues.


name: Bipolar Disorder, in Full Remission, Most Recent Episode Manic

description: Evidence of bipolar disorder, in full remission, most recent episode manic.


tabtoxinine-delta-lactam

A delta-lactam that is L-pipecolic acid carrying additional hydroxy and aminomethyl substituents at position 5 as well as an oxo substituent at position 6.


Childhood Posterior Fossa Ependymoma

description: A posterior fossa ependymoma that occurs during childhood.


N-methylfentanyl

The monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of 1-methyl-N-phenylpiperidin-4-amine with propanoic acid.


LEUPROLIDE ACETATE

An acetate salt obtained by combining the nonapeptide leuprolide with acetic acid. A long lasting GnRH analog, LH-Rh agonist. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.


name: Melanoma of the Ciliary Body and Choroid pT3b TNM Finding v7

description: Tumor size category 3 with ciliary body involvement. (from AJCC 7th Ed.)


name: Melanoma of the Uvea Pathologic Primary Tumor TNM Finding v7

description: A pathologic finding about one or more characteristics of melanoma of the uvea, following the rules of the TNM AJCC v7 classification system as they pertain to staging of the primary tumor.


name: Melanoma of the Iris pT4a TNM Finding v7

description: Melanoma of the iris with extrascleral extension less than or equal to 5 mm in diameter. (from AJCC 7th Ed.)


name: Melanoma of the Ciliary Body and Choroid pT3a TNM Finding v7

description: Tumor size category 3 without ciliary body involvement and extraocular extension. (from AJCC 7th Ed.)


name: Melanoma of the Iris pT4b TNM Finding v7

description: Melanoma of the iris with extrascleral extension more than 5 mm in diameter. (from AJCC 7th Ed.)


name: Melanoma of the Iris pT1a TNM Finding v7

description: Melanoma of the iris with tumor limited to the iris not more than 3 clock hours in size. (from AJCC 7th Ed.)


name: Melanoma of the Ciliary Body and Choroid Pathologic Primary Tumor TNM Finding v7

description: A pathologic finding about one or more characteristics of melanoma of the ciliary body and choroid, following the rules of the TNM AJCC v7 classification system as they pertain to staging of the primary tumor.


name: Melanoma of the Iris pT3a TNM Finding v7

description: Melanoma of the iris with tumor confluent with or extending into the ciliary body, choroid, or both, with sclera extension and secondary glaucoma. (from AJCC 7th Ed.)


name: Melanoma of the Ciliary Body and Choroid pT4d TNM Finding v7

description: Tumor size category 4 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter. (from AJCC 7th Ed.)


name: Melanoma of the Ciliary Body and Choroid pTX TNM Finding v7

description: Melanoma of the ciliary body and choroid in which the primary tumor cannot be assessed. (from AJCC 7th Ed.)


name: Melanoma of the Ciliary Body and Choroid pT4b TNM Finding v7

description: Tumor size category 4 with ciliary body involvement. (from AJCC 7th Ed.)


Melanoma of the Iris pT2 TNM Finding v7

description: Melanoma of the iris with tumor confluent with or extending into the ciliary body, choroid, or both. (from AJCC 7th Ed.)


Melanoma of the Iris pT0 TNM Finding v7

description: Melanoma of the iris with no evidence of a primary tumor. (from AJCC 7th Ed.)


name: Melanoma of the Iris Pathologic Primary Tumor TNM Finding v7

description: A pathologic finding about one or more characteristics of melanoma of the iris, following the rules of the TNM AJCC v7 classification system as they pertain to staging of the primary tumor.


name: Melanoma of the Ciliary Body and Choroid pT4e TNM Finding v7

description: Any tumor size category with extraocular extension more than 5 mm in diameter. (from AJCC 7th Ed.)


name: Melanoma of the Ciliary Body and Choroid pT3c TNM Finding v7

description: Tumor size category 3 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter. (from AJCC 7th Ed.)


name: Melanoma of the Iris pT1b TNM Finding v7

description: Melanoma of the iris with tumor limited to the iris more than 3 clock hours in size. (from AJCC 7th Ed.)


Melanoma of the Iris pT3 TNM Finding v7

description: Melanoma of the iris with tumor confluent with or extending into the ciliary body, choroid, or both, with sclera extension. (from AJCC 7th Ed.)


name: Melanoma of the Ciliary Body and Choroid pT4c TNM Finding v7

description: Tumor size category 4 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter. (from AJCC 7th Ed.)


name: Melanoma of the Ciliary Body and Choroid pT0 TNM Finding v7

description: Melanoma of the ciliary body and choroid with no evidence of a primary tumor. (from AJCC 7th Ed.)


name: Melanoma of the Ciliary Body and Choroid pT4 TNM Finding v7

description: Tumor size category 4. (from AJCC 7th Ed.)


name: Melanoma of the Iris pT1c TNM Finding v7

description: Melanoma of the iris with tumor limited to the iris with secondary glaucoma. (from AJCC 7th Ed.)


name: Melanoma of the Iris pT2a TNM Finding v7

description: Melanoma of the iris with tumor confluent with or extending into the ciliary body, choroid, or both, with secondary glaucoma. (from AJCC 7th Ed.)


Melanoma of the Iris pT4 TNM Finding v7

description: Melanoma of the iris with extrascleral extension. (from AJCC 7th Ed.)


name: Melanoma of the Ciliary Body and Choroid pT3 TNM Finding v7

description: Tumor size category 3. (from AJCC 7th Ed.)


name: Melanoma of the Ciliary Body and Choroid pT4a TNM Finding v7

description: Tumor size category 4 without ciliary body involvement and extraocular extension. (from AJCC 7th Ed.)


Melanoma of the Iris pT1 TNM Finding v7

description: Melanoma of the iris with tumor limited to the iris. (from AJCC 7th Ed.)


name: Melanoma of the Ciliary Body and Choroid pT3d TNM Finding v7

description: Tumor size category 3 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter. (from AJCC 7th Ed.)


AMINOHIPPURATE SODIUM

An organic sodium salt that is the monosodium salt of p-aminohippuric acid.


double-walled carbon nanotube

A carbon nanotube consisting of two concentric graphene cylinders.


multi-walled carbon nanotube

A molecule consisting of three or more concentric graphene cylinders.


carbon nanorope

A carbon nanostructure consisting of carbon nanotubes which have been spun or bundled together.


zigzag carbon nanotube

A single walled carbon nanotube with (n,m) indices equal to (n,0) or (0,m). Zigzag carbon nanotubes have a chiral angle of 0degree and can be either metallic or semiconducting.


carbon nanofibre

A carbon nanostructure consisting of layers of stacked graphite cones or plates.


carbon nanohorn

A single-walled carbon nanostructure with an irregular horn-like shape.


armchair carbon nanotube

A single-walled carbon nanotube with equal n and m indices. Armchair carbon nanotubes have a chiral angle of 30degree and are metallic.


carbon black nanoparticle

Any form of carbon black which has a particle size of less than 100 nm in each dimension.


metallic single-walled carbon nanotube

A single-walled carbon nanotube with (n,m) indices such that n-m is a multiple of 3.


chiral carbon nanotube

A single-walled carbon nanotube with unequal (n,m) indices and a chiral angle of between 0 and 30degree.


single-walled carbon nanotube

A carbon nanotube consisting of a single graphene cylinder. Different kinds of single-walled carbon nanotube are distinguished by the indices (n,m) which describe the vector along which the graphene is rolled. The chiral angle is the angle between the vector and the origin and can take any value between 0 and 30degree.


name: semiconducting single-walled carbon nanotube

description: A single-walled carbon nanotube with (n,m) indices such that n-m is not a multiple of 3.


vanilloyl-CoA

A member of the class of benzoyl-CoAs having 4-hydroxy-3-methoxybenzoyl (also known as vanilloyl) as the aroyl group. A potential intermediate of vanillate biosynthesis.


Neonatal Tachyarrhythmia, AE

description: An adverse event in a newborn characterized by non-sinus rhythm with an abnormally high heart rate for age.


Grade 4 Neonatal Tachyarrhythmia, AE

description: A tachyarrhythmia adverse event in a newborn characterized by life-threatening consequences (e.g. shock); requiring urgent major care changes.


Grade 5 Neonatal Tachyarrhythmia, AE

description: A tachyarrhythmia adverse event in a newborn which results in death.


Grade 3 Neonatal Tachyarrhythmia, AE

description: A tachyarrhythmia adverse event in a newborn resulting in non-life threatening hemodynamic compromise or changes in age-appropriate behavior; requiring major care changes (e.g. new medication or intervention).


Grade 2 Neonatal Tachyarrhythmia, AE

description: A tachyarrhythmia adverse event in a newborn characterized by no change in age-appropriate behavior; requiring minor care changes (e.g. increased monitoring).


Grade 1 Neonatal Tachyarrhythmia, AE

description: An adverse event in a newborn characterized by brief, self-limiting, episodes of asymptomatic tachyarrhythmia (e.g. extra-systolic beats); no care changes.


Increased NFkappaB Pathway Activation

description: A genetic finding indicating that there is increased activation of the NFkappaB pathway.


lanthionine ketimine

A member of the class of 1,4-thiazines that is 3,6-dihydro-2H-1,4-thiazine substituted by carboxy groups at positions 3 and 5. It is a natural but non-proteogenic amino acid found in human urine and brain.


Adult Benign Brain Stem Neoplasm

description: A benign neoplasm of the brain stem occurring in adults.


Medullary Hemangioblastoma

description: A hemangioblastoma that arises from the medulla oblongata.


Childhood Brain Stem Gliosarcoma

description: A gliosarcoma that arises from the brain stem and occurs during childhood.


Childhood Brain Stem Mixed Glioma

description: A mixed glioma that arises from the brain stem and occurs during childhood.


name: Metastatic malignant neoplasm to brain stem

description: A malignant neoplasm that has spread from its original site of growth to the brain stem.


Recurrent Childhood Brain Stem Glioma

description: The reemergence of brain stem glioma in childhood after a period of remission.


Anaplastic Brain Stem Astrocytoma

description: An anaplastic astrocytoma that arises from the brain stem.


Brain Stem Glioblastoma

description: A glioblastoma that arises from the brain stem.


Anaplastic Brain Stem Glioma

description: An anaplastic glioma that arises from the brain stem.


The simplest member of the class of 2-hydroxy-1,4-benzoquinones, that is 1,4-benzoquinone in which a single hydrogen is replaced by a hydroxy group.


name: Grade 5 External Ear Infection with Normal Absolute Neutrophil Count or Grade 1 or 2 Neutrophils, CTCAE


Recurrent Acute Bilineal Leukemia

description: The reemergence of acute bilineal leukemia after a period of remission.


name: Recurrent Mixed Phenotype Acute Leukemia

description: The reemergence of mixed phenotype acute leukemia after a period of remission.


acute biphenotypic leukemia in relapse

description: The reemergence of acute biphenotypic leukemia after a period of remission.


name: Grade 4 Oral Cavity NOS Intra-Operative Injury, CTCAE


Grade 3 Glaucoma, CTCAE

description: EIOP causing visual field deficits


Grade 4 Hypomagnesemia, CTCAE

description: <0.7 mg/dL; <0.3 mmol/L; life-threatening consequences


An N-acyl-15-methylhexadecasphing-4-enine-1-phosphocholine in which the acyl group has 21 carbons and 1 double bond.


name: Leakage of Heart Valve Prosthesis, Subsequent Encounter

description: Evidence of leakage of heart valve prosthesis, subsequent encounter.


sodium gluconate

An organic sodium salt having D-gluconate as the counterion.


dopamine 3-O-sulfate

An aryl sulfate that is dopamine in which the phenolic hydrogen at position 3 has been replaced by a sulfo group.


Cervical Cancer cN1 TNM Finding v7

description: Cervical cancer with regional lymph node metastasis. (from AJCC 7th Ed.)


A member of the class of coumarins  that consists of coumarin substituted by a senecioyloxymethyl group at position 4 and methoxy groups at positions 6 and 7. Isolated from Crinum latifolium, it exhibits anti-angiogenic activity.


name: Ampulla of Vater Neuroendocrine Tumor G3

description: A well differentiated, high grade neoplasm with neuroendocrine differentiation that arises from the ampulla of Vater and the periampullary region. The Ki-67 index is higher than 20%.


name: Low Risk Small Intestinal Gastrointestinal Stromal Tumor


name: Low Risk Esophageal Gastrointestinal Stromal Tumor


name: Low Risk Colorectal Gastrointestinal Stromal Tumor


name: Low Risk Gastric Gastrointestinal Stromal Tumor


perfluoropentanoic acid

A monocarboxylic acid that is perfluorinated pentanoic acid.


An  indole alkaloid that is canthin-6-one substituted by a hydroxy group at position 9. Isolated from the roots of Eurycoma longifolia, it exhibits antineoplastic activity.


CRATOXYARBORENONE C

A member of the class of xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1 and 3, methoxy groups at positions 5 and 7 and two isoprenyl groups at positions 2 and 8 respectively. It is isolated from Cratoxylum Sumatranum and exhibits cytotoxicity towards the KB (human oral epidermoid) cancer cell line


name: Dysphasia following Unspecified Cerebrovascular Disease

description: Evidence of dysphasia following unspecified cerebrovascular disease.


A glucosylglycerol phosphate consisting of sn-glycerol 3-phosphate having a beta-D-glucosyl residue attached at position 2.


name: 4-amino-1,2,5-oxadiazole-3-carboxylic acid [2-(2,6-dimethylanilino)-2-oxoethyl] ester


A glycohexaosylceramide having beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-Glc as the glycohexaosyl component.


name: Fluency Disorder following Cerebral Infarction

description: Evidence of fluency disorder following cerebral infarction.


Ser-Trp-Lys

A tripeptide formed from L-serine, L-tryptophan and L-lysine residues joined in sequence by peptide linkages.


description: Evidence of secondary malignant neoplasm of other parts of nervous system.


hexadecanedioic acid

An alpha,omega-dicarboxylic acid that is the 1,14-dicarboxy derivative of tetradecane.


name: Pancreatic Intraductal Papillary Mucinous Neoplasm, Pancreatobiliary-Type

description: A pancreatic intraductal papillary mucinous neoplasm characterized by the presence of neoplastic epithelial cells that form thin-branching papillae and exhibit high grade dysplasia.


name: Pancreatic Intraductal Papillary Mucinous Neoplasm, Gastric-Type

description: A pancreatic intraductal papillary mucinous neoplasm characterized by the presence of neoplastic epithelial cells that are similar to gastric foveolar epithelial cells.


name: Branch Duct Pancreatic Intraductal Papillary-Mucinous Neoplasm

description: An intraductal papillary-mucinous neoplasm of the pancreas that arises in one of the branches of the main pancreatic duct.  It usually has an indolent behavior.


name: Mixed Type Pancreatic Intraductal Papillary-Mucinous Neoplasm

description: An intraductal papillary-mucinous neoplasm of the pancreas that arises primarily from the main pancreatic duct and extends to the branch ducts.


name: Pancreatic Intraductal Papillary Mucinous Neoplasm, Oncocytic-Type

description: A pancreatic intraductal papillary mucinous neoplasm characterized by the presence of neoplastic epithelial cells with abundant eosinophilic granular cytoplasm.


name: Main Duct Pancreatic Intraductal Papillary-Mucinous Neoplasm

description: An intraductal papillary-mucinous neoplasm of the pancreas that arises from the main pancreatic duct.


name: Pancreatic Intraductal Papillary Mucinous Neoplasm, Intestinal-Type

description: A pancreatic intraductal papillary mucinous neoplasm characterized by the presence of neoplastic epithelial cells that form tall papillae, similar to those that are present in colonic villous adenomas.


Advanced Rhabdoid Tumor

description: Rhabdoid tumor that has spread extensively to other anatomic sites or is no longer responding to treatment.


Metastatic Rhabdoid Tumor

description: A rhabdoid tumor that has spread from the original site of growth to another anatomic site.


beta-D-rhamnofuranose

A D-rhamnofuranose having beta-configuration at the anomeric centre.


name: sialadenoma papilliferum of salivary gland

description: An uncommon exophytic papillary proliferation that involves mucosal surface epithelium and salivary duct epithelium. It is exceptional among salivary gland neoplasms because it manifests as an exophytic papillary excrescence of the mucosa, rather than as a submucosal or intraglandular mass. It most often affects the hard or soft palate.  It is generally asymptomatic.


C-type aurachin

Any aurachin in which the farnesyl residue is positioned at C3 of the quinoline core (cf. A-type aurachin, in which the farnesyl residue is positioned at C4). C-type aurachins are converted into A-type aurachins by late stage tailoring reactions.


aurachin

Compounds comprising a class of isoprenoid quinoline alkaloids originally isolated from the myxobacterium Stigmatella aurantiaca together with their semi-synthetic and fully synthetic analogues. They are divided into A-type or C-type aurachins according to the position of the farnesyl residue either at C4 or C3 of the quinoline core, respectively.


AURACHIN B

An A-type aurachin that is quinoline N-oxide which is substituted by a methyl group at position 2, a hydroxy group at position 3, and a triprenyl group at position 4.


A-type aurachin

Any aurachin in which the farnesyl residue is positioned at C4 of the quinoline core (cf. C-type aurachin, in which the farnesyl residue is positioned at C3). C-type aurachins are converted into A-type aurachins by late stage tailoring reactions.


AURACHIN C

A C-type aurachin that is quinolin-4-one which is substituted by a hydroxy group at positions 1, a methyl group at position 2, and a triprenyl group at position 3.


Elevated Sedimentation Rate

description: A higher than average sedimentation rate in a sample.


A phosphine oxide in which the substituents on phosphorus are 4-carboxybut-1-yn-1-yl, methyl and 2-methoxyphenyl.


RAF Wild Type

description: A genetic finding indicating that RAF family gene mutations are absent in a sample.


BRAF Gene Mutation Negative

description: A genetic finding indicating that BRAF gene mutations have not been detected in a sample.


Abscess Leakage

description: The loss of a fluid from an abscess into the surrounding tissue or body cavity.


name: migraine with or without aura, susceptibility to, 5


phosphatidylcholine (17:0/22:6)

A phosphatidylcholine 39:6 in which the fatty acyl groups at positions 1 and 2 are specified as C17:0 and C22:6 respectively.


name: Low Grade Malignant Peripheral Nerve Sheath Tumor

description: A malignant peripheral nerve sheath tumor that is low-grade.


A glycophytoceramide having an alpha-D-galactopyranosyl residue at the O-1 position and a tetracosanoyl group attached to the nitrogen.


Grade 1 Genital Edema, CTCAE

description: Mild swelling or obscuration of anatomic architecture on close inspection


disulfur dinitride

An inorganic heterocyclic compound with formula N2S2 and consisting of alternating sulfur and nitrogen atoms making up a 4-membered ring structure that is virtually square and planar. It is shock-sensitive and decomposes explosively above 30degreeC.


name: Grade 1 Bruising in the Absence of Grade 3 or Grade 4 Thrombocytopenia, CTCAE


Tentorial Tear Related to Birth

description: Disruption of the tentorium cerebelli incurred during delivery.


Grade 2 Pericardial Effusion, CTCAE

description: Asymptomatic effusion size small to moderate


A beta-D-glucosyl-N-acylsphingosine in which the acyl group is specified as tetracosanoyl.


Breast Cancer pM1 TNM Finding v8

description: Breast cancer with distant metastases detected by clinical and radiographic means and/or histologically proven metastases larger than 0.2 mm. (from AJCC 8th Ed.)


name: Breast Cancer Pathologic Distant Metastasis TNM Finding v8

description: A pathologic finding about one or more characteristics of breast cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.


name: Direct Infection of Unspecified Knee in Infectious and Parasitic Diseases Classified Elsewhere

description: Evidence of direct infection of unspecified knee in infectious and parasitic diseases classified elsewhere.


A member of the class of pyrimidine ribonucleosides that is zebularine in which the double bond between positions 3 and 4 of the pyrimidone ring has been reduced to a single bond.


glufosinate-P-ammonium

An ammonium salt resulting from the formal reaction of equimolar amounts of glufosinate-P and ammonia. A glutamine synthetase inhibitor, used as a herbicide to control annual weeds and grasses.


name: Classic Hydroa Vacciniforme Lymphoproliferative Disorder

description: Hydroa vacciniforme lymphoproliferative disorder characterized by the presence of self-limited papulovesicular skin lesions in sun-exposed areas. There is no involvement of internal organs. It has an indolent course and usually affects White individuals.


A polyunsaturated fatty aldehyde that is nonanal which has 3 double bonds at positions 2, 4 and 6. The configuration of the double bonds is unknown.


polyunsaturated fatty aldehyde

Any fatty aldehyde containing more than one double or triple bond located at any position in the aliphatic chain.


A polyunsaturated fatty aldehyde that is heptadecenal having three double bonds located at postions 8, 11 and 14 (the 8Z,11Z,14Z-geoisomer).


A nona-2,4,6-trienal in which all three double bonds adopt trans-configurations.


A polyunsaturated fatty aldehyde that is (2E,6E,8E,10E)-dodeca-2,6,8,10-tetraenal in which the pro-S hydrogen at position 5 has been replaced by a hydroxy group.


tetradecadienal

Any C14 polyunsaturated fatty aldehyde containing two double bonds.


octadecadienal

Any C18 polyunsaturated fatty aldehyde containing two double bonds.


A polyunsaturated fatty aldehyde that is hexadecadienal in which the two double bonds are located at positions 10 and 12 (the 10Z,12E-geoisomer).


A polyunsaturated fatty aldehyde that is octanal which has 3 double bonds at positions 2, 4 and 6. The configuration of the double bonds is unknown.


A tetradecadienal with double bonds at positions 5 and 8.


A polyunsaturated fatty aldehyde that is decanal which has undergone formal dehydrogenation to introduce trans- double bonds at the 2-3 and 4-5 positions. A product of lipid peroxidation in cell membranes and a component of cooking oil fumes.


name: Stringent Complete Response (sCR) of Multiple Myeloma or Plasma Cell Leukemia

description: Stringent complete response (sCR) of multiple myeloma or plasma cell leukemia is characterized by complete response plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence (confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the kappa/lambda ratio. An abnormal kappa/lambda ratio by immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting the presence of an abnormal clone is kappa/lambda of > 4:1 or < 1:2.).  Stringent complete response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy stringent complete response requirements.


Stringent Complete Response

description: The confirmed disappearance of all signs of cancer, and absence of molecular or cytogenetic marker of disease, in response to treatment with additional biochemical, immunological and histopathological analyses to verify the CR.


name: Other specified types of non-Hodgkin lymphoma, intrapelvic lymph nodes

description: Evidence of other specified types of non-Hodgkin lymphoma in the intrapelvic lymph nodes not specified elsewhere.


name: 3-pyridinecarboxylic acid [2-(2-furanyl)-4-oxo-1-benzopyran-3-yl] ester


Stage II Childhood Hodgkin Lymphoma

description: Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE).


trans-(S)-nicotine N(1')-oxide

An (S)-nicotine N(1')-oxide in which the N(1')-methyl group is on the opposite side of the pyrrolidine ring to the pyridine substituent. The major species at pH 7.3.


pyrrolidine N-oxides

Any member of the class of pyrrolidines that are substituted by an organyl group at position 1 and in which the amino group of the pyrrolidine ring has been oxidised to give the corresponding N-oxide.


(S)-nicotine N(1')-oxide

A nicotine N(1')-oxide resulting from the oxidation of the pyrrolidine nitrogen of (S)-nicotine; major species at pH 7.3.


cis-(S)-nicotine N(1')-oxide

An (S)-nicotine N(1')-oxide in which the N(1')-methyl group is on the same side of the pyrrolidine ring as the pyridine substituent. The major species at pH 7.3.


Carsickness

description: A sensation of discomfort associated with ground travel; symptoms may include nausea, vomiting, dizziness or sweating.


name: Grade 1 Appendix Intra-Operative Injury, CTCAE


An O-acylcarnitine compound having 2-ethylacryloyl as the acyl substituent.


name: Refractory Paranasal Sinus Squamous Cell Carcinoma

description: Paranasal sinus squamous cell carcinoma that does not respond to treatment.


name: Refractory Head and Neck Squamous Cell Carcinoma

description: A head and neck squamous cell carcinoma that does not respond to treatment.


name: Refractory Sinonasal Squamous Cell Carcinoma

description: Nasal cavity and paranasal sinus squamous cell carcinoma that does not respond to treatment.


name: Refractory Oral Cavity Squamous Cell Carcinoma

description: Oral cavity squamous cell carcinoma that does not respond to treatment.


name: Refractory Cutaneous Squamous Cell Carcinoma of the Head and Neck

description: Cutaneous squamous cell carcinoma of the head and neck that does not respond to treatment.


Hodgkin's lymphoma of small intestine

description: A Hodgkin lymphoma that arises from the small intestine.


name: Resectable Pancreatic Acinar Cell Carcinoma

description: Pancreatic acinar cell carcinoma that is amenable to surgical resection.


Pancreas carcinoma resectable

description: Carcinoma of the pancreas amenable to surgical removal.


name: Borderline Resectable Pancreatic Ductal Adenocarcinoma

description: A pancreatic ductal adenocarcinoma term that refers to a continuum between resectable and locally advanced unresectable disease.


Pancreatic adenocarcinoma resectable

description: Pancreatic adenocarcinoma that is amenable to surgical resection.


name: Resectable Pancreatic Ductal Adenocarcinoma

description: Pancreatic ductal adenocarcinoma amenable to surgical resection.


name: Resectable Pancreatic Adenosquamous Carcinoma

description: Pancreatic adenosquamous carcinoma that is amenable to surgical resection.


A tetrahydromethanopterin having a methanylylidene joined to the nitrogens at the 5- and 10-positions.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (15R)-15-hydroxypalmitic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.


tetranorbiotin

A member of the class of thienoimidazoles that is 2-oxohexahydrothieno[3,4-d]imidazole carrying an additional carboxy group at position 4 (the 3aS,4R,6aR-diastereomer).


thienoimidazole

Any organic heterobicyclic compound that consists of an imidazole ring -fused to a thiophene ring.


Ovarian Cancer pT2a TNM Finding v6

description: Ovarian cancer involving one or both ovaries with extension or implants on uterus and/or fallopian tubes and without malignant cells in ascites or peritoneal washings. (from AJCC 6th Ed.)


name: Female Reproductive System Cancer TNM Finding v6

description: A finding about one or more characteristics of female reproductive system cancer, following the rules of the TNM AJCC v6 classification system.


Ovarian Cancer pT3a TNM Finding v6

description: Ovarian cancer involving one or both ovaries with microscopically confirmed peritoneal metastasis beyond the pelvis. (from AJCC 6th Ed.)


name: Uterine Corpus Cancer pMX TNM Finding v6

description: Uterine corpus cancer in which distant metastasis cannot be assessed. (from AJCC 6th Ed.)


name: Uterine Corpus Cancer pN1 TNM Finding v6

description: Uterine corpus cancer with metastasis to the pelvic or para-aortic lymph nodes. (from AJCC 6th Ed.)


Ovarian Cancer pT1c TNM Finding v6

description: Ovarian cancer involving one or both ovaries with either a ruptured capsule, or tumor on the ovarian surface, or presence of malignant cells in either ascites or peritoneal washings. (from AJCC 6th Ed.)


name: Uterine Corpus Cancer pNX TNM Finding v6

description: Uterine corpus cancer in which regional lymph nodes cannot be assessed. (from AJCC 6th Ed.)


Uterine Corpus Cancer pM0 TNM Finding

description: Uterine corpus cancer in which there is no evidence of distant metastasis. (from AJCC 6th Ed.)


name: Uterine Corpus Cancer pM1 TNM Finding v6

description: Uterine corpus cancer with distant metastasis, including intra-abdominal lymph nodes other than para-aortic or inguinal lymph nodes, excluding metastasis to the vagina, pelvic serosa, or adnexa. (from AJCC 6th Ed.)


name: Ovarian Cancer Pathologic Distant Metastasis TNM Finding v6

description: A pathologic finding about one or more characteristics of ovarian cancer, following the rules of the TNM AJCC v6 classification system as they pertain to distant metastases. TNM pathologic distant metastasis findings are based on clinical findings supplemented by histopathologic examination of one or more tissue specimens acquired during surgery.


Ovarian Cancer pT1 TNM Finding v6

description: Ovarian cancer with tumor confined to one or both ovaries. (from AJCC 6th Ed.)


name: Uterine Corpus Cancer Clinical TNM Finding v6

description: A clinical finding about one or more characteristics of uterine corpus cancer, following the rules of the TNM AJCC v6 classification system. TNM clinical findings are based on information obtained prior to the first definitive treatment through physical examination, diagnostic imaging, biopsy and laboratory testing.


Ovarian Cancer pT3c TNM Finding v6

description: Ovarian cancer involving one or both ovaries with macroscopic peritoneal metastasis beyond the pelvis, with tumor size of more than 2 cm in greatest dimension. (from AJCC 6th Ed.)


Ovarian Cancer Clinical TNM Finding v6

description: A clinical finding about one or more characteristics of ovarian cancer, following the rules of the TNM AJCC v6 classification system. TNM clinical findings are based on information obtained prior to the first definitive treatment through physical examination, diagnostic imaging, biopsy or laboratory testing.


name: Ovarian Cancer Pathologic Regional Lymph Nodes TNM Finding v6

description: A pathologic finding about one or more characteristics of ovarian cancer, following the rules of the TNM AJCC v6 classification system as they pertain to staging of regional lymph nodes.


Ovarian Cancer pN0 TNM Finding v6

description: Ovarian cancer without involvement of regional lymph nodes. (from AJCC 6th Ed.)


name: Uterine Corpus Cancer Pathologic Regional Lymph Nodes TNM Finding v6

description: A pathologic finding about one or more characteristics of uterine corpus cancer, following the rules of the TNM AJCC v6 classification system as they pertain to staging of regional lymph nodes. TNM pathologic regional lymph nodes findings are based on clinical findings supplemented by histopathologic examination of one or more tissue specimens acquired during surgery.


Ovarian Cancer pTX TNM Finding v6

description: Ovarian cancer in which the primary tumor cannot be assessed. (from AJCC 6th Ed.)


Ovarian Cancer TNM Finding v6

description: A finding about one or more characteristics of ovarian cancer, following the rules of the TNM AJCC v6 classification system.


Ovarian Cancer pMX TNM Finding v6

description: Ovarian cancer in which distant metastasis cannot be assessed. (from AJCC 6th Ed.)


name: Uterine Corpus Cancer Pathologic TNM Finding v6

description: A pathologic finding about one or more characteristics of uterine corpus cancer, following the rules of the TNM AJCC v6 classification system. TNM pathologic findings are based on clinical findings supplemented by histopathologic examination of one or more tissue specimens acquired during surgery.


Ovarian Cancer pN1 TNM Finding v6

description: Ovarian cancer with metastasis to one or more regional lymph nodes. (from AJCC 6th Ed.)


Ovarian Cancer pT2b TNM Finding v6

description: Ovarian cancer involving one or both ovaries with extension or implants on pelvic tissues other than the uterus or fallopian tubes, and without malignant cells in ascites or peritoneal washings. (from AJCC 6th Ed.)


name: Uterine Corpus Cancer Pathologic Distant Metastasis TNM Finding v6

description: A pathologic finding about one or more characteristics of uterine corpus cancer, following the rules of the TNM AJCC v6 classification system as they pertain to distant metastases. TNM pathologic distant metastasis findings are based on clinical findings supplemented by histopathologic examination of one or more tissue specimens acquired during surgery.


name: Ovarian Cancer Pathologic TNM Finding v6

description: A pathologic finding about one or more characteristics of ovarian cancer, following the rules of the TNM AJCC v6 classification system.


Ovarian Cancer pT3 TNM Finding v6

description: Ovarian cancer involving one or both ovaries with microscopic or macroscopic peritoneal metastasis beyond the pelvis. (from ACJCC 6th Ed.)


name: Uterine Corpus Cancer pN0 TNM Finding v6

description: Uterine corpus cancer in which there is no evidence of regional lymph node metastasis. (from AJCC 6th Ed.)


Ovarian Cancer pT0 TNM Finding v6

description: Ovarian cancer with no evidence of a primary tumor. (from AJCC 6th Ed.)


Ovarian Cancer pT1b TNM Finding v6

description: Ovarian cancer with tumor in both ovaries with capsule intact, no tumor on ovarian surface and no malignant cells in either ascites or peritoneal washings. The presence of ascites does not affect staging unless malignant cells are present. (from AJCC 6th Ed.)


Ovarian Cancer pT1a TNM Finding v6

description: Ovarian cancer with tumor in one ovary with capsule intact, no tumor on ovarian surface and no malignant cells in either ascites or peritoneal washings. The presence of ascites does not affect staging unless malignant cells are present. (from AJCC 6th Ed.)


Ovarian Cancer pNX TNM Finding v6

description: Ovarian cancer in which the regional lymph nodes cannot be assessed. (from AJCC 6th Ed.)


Ovarian Cancer pT2 TNM Finding v6

description: Ovarian cancer involving one or both ovaries with pelvic extension and/or implants. (from AJCC 6th Ed.)


Ovarian Cancer pT2c TNM Finding v6

description: Ovarian cancer involving one or both ovaries with extension or implants on the uterus and/or fallopian tubes, or other pelvic tissues, with malignant cells in either ascites or peritoneal washings. (from AJCC 6th Ed.)


name: Ovarian Cancer Pathologic Primary Tumor TNM Finding v6

description: A pathologic finding about one or more characteristics of ovarian cancer, following the rules of the TNM AJCC v6 classification system as they pertain to staging of the primary tumor. TNM pathologic primary tumor findings are based on clinical findings supplemented by histopathologic examination of one or more tissue specimens acquired during surgery.


Ovarian Cancer pT3b TNM Finding v6

description: Ovarian cancer involving one or both ovaries with macroscopic peritoneal metastasis beyond the pelvis, with tumor size of 2 cm or less in greatest dimension. (from AJCC 6th Ed.)


coelichelin

A tetrapeptide hydroxamate siderophore that is isolated from Streptomyces coelicolor.


fatty alcohol 20:1

Any fatty alcohol containing 20 carbons and 1 double bond.


A fatty alcohol 20:1 that is icosanol containing a double bond located at position 11 (the 11Z-geoisomer).


A ceramide phosphoinositol compound having a tetracosanoyl group amide-linked to a C20 phytosphingosine base, with hydroxylation at C-2 of the C24 very-long-chain fatty acid.


description: Evidence of myeloid sarcoma not having achieved remission.


name: Stage I Lip and Oral Cavity Cancer AJCC v8

description: Stage I includes: T1, N0, M0.  T1: Tumor size 2 cm or less in greatest dimension and 5 mm or less depth of invasion (DOI).  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 8th Ed.)


name: Grade 2 Parotid Gland Intra-Operative Injury, CTCAE


Brain Pilocytic Astrocytoma

description: Pilocytic astrocytoma that arises from the brain.


Third Ventricle Pilocytic Astrocytoma

description: A pilocytic astrocytoma occurring in the third ventricle.


name: 2-[(5-chloro-2-thiophenyl)-oxomethyl]imino-3,4-dimethyl-5-thiazolecarboxylic acid ethyl ester


name: Malignant Neoplasm of Connective and Soft Tissue of Left Lower Limb, Including Hip

description: Evidence of a malignant neoplasm of connective and soft tissue of left lower limb including the hip.


name: Hemolytic anemia due to disseminated intravascular coagulation


Anemia due to membrane defect

description: A group of inherited hemolytic anemias caused by erythrocyte membrane defects. This includes hereditary pyropoikilocytosis, hereditary spherocytosis and hereditary elliptocytosis.


Immune Hemolytic Anemia

description: An acquired anemia resulting from immune-mediated destruction of the red blood cells. Causes include autoimmune disorders, blood transfusions, and drugs.


Anemia, Hemolytic, Acquired

description: Hemolytic anemia, the cause of which is not present at birth.


Infantile pyknocytosis

description: A rare, neonatal syndrome characterized by early jaundice that becomes rapidly associated with severe hemolytic anemia. The peripheral blood smear is remarkable for small irregular, contracted red blood cells with hyper-dense spikes (pyknocytes), that progressively increase in number and then spontaneously disappear.


HLA-A*02:642 Positive Cells Present

description: A laboratory test result indicating the presence of HLA-A*02:642 positive cells in a tissue sample.


Refractory Lymphomatoid Granulomatosis

description: Lymphomatoid granulomatosis that is resistant to treatment.


name: Angiocentric immunoproliferative lesion grade 2

description: Lymphomatoid granulomatosis characterized by the presence of occasional large lymphoid cells or immunoblasts in a polymorphous background. Necrosis is more commonly seen as compared to grade I lymphomatoid granulomatosis. By in situ hybridization, EBV-positive cells are readily seen.


name: Central Nervous System Lymphomatoid Granulomatosis

description: Lymphomatoid granulomatosis that affects the brain, spinal cord, and leptomeninges.


Cutaneous Lymphomatoid Granulomatosis

description: Lymphomatoid granulomatosis that affects the skin.


Childhood Lymphomatoid Granulomatosis

description: Lymphomatoid granulomatosis that occurs during childhood.


propionyl-CoA

An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of propionic acid.


name: Grade 2 Fallopian Tube Obstruction, CTCAE

description: Symptomatic; elective intervention indicated


Fallopian Tube Obstruction, CTCAE 5.0

description: A disorder characterized by blockage of the normal flow of the contents in the fallopian tube.


name: Grade 1 Fallopian Tube Obstruction, CTCAE

description: Asymptomatic; clinical or diagnostic observations only; intervention not indicated


name: Grade 3 Fallopian Tube Obstruction, CTCAE

description: Severe symptoms; invasive intervention indicated


CINANSERIN HYDROCHLORIDE

The hydrochloride salt of cinanserin. It is an inhibitor of 3C-like proteinase of severe acute respiratory syndrome coronavirus (SARS-Cov) and reduces virus replication in vitro.


5-fluorouridine 5'-monophosphate

A pyrimidine ribonucleoside 5'-monophosphate having 5-fluorouracil as the pyrimidine component.


name: High Grade Anal Canal Intraepithelial Neoplasia

description: Intraepithelial neoplasia involving the anal canal.  The epithelial cells exhibit moderate dysplasia (grade II intraepithelial neoplasia) or severe dysplasia (grade III intraepithelial neoplasia or carcinoma in situ).


MULTIPLOLIDE B

A 10-membered lactone obtained from 10-methyl-9,10-dihydro-2H-oxecin-2-one by the epoxidation of the double bond at position 3-4 and cis-dihydroxylation of the double bond at position 7-8, with further acylation of the hydroxy group at position 8 by a but-2-enoyl group. Multiplolide B was first isolated from the fungus Xylaria multiplex BCC 1111. It shows antifungal activity against Candida albicans. The epoxide group has cis-configuration, but its configuration relative to the other substituents was not established.


DEAMINOHYDROXYVALINE

The R-enantiomer of 2-hydroxy-3-methylbutyric acid.


diphenylethane

Compounds containing two phenyl groups connected by an ethyl linker.


name: 2-[[cyclohexyl(oxo)methyl]amino]acetic acid (2-oxo-1,2-diphenylethyl) ester


name: 2-phenoxyacetic acid (2-oxo-1,2-diphenylethyl) ester


name: 3-acetamidobenzoic acid [2-(4-methylphenyl)-2-oxo-1-phenylethyl] ester


name: 2-chlorobenzoic acid [2-(4-methoxyphenyl)-2-oxo-1-phenylethyl] ester


DIHYDROPINOSYLVIN

A member of the class of resorcinols carrying an additional 2-phenylethyl substituent at position 5.


benzoin

A ketone that consists of acetophenone bearing hydroxy and phenyl substituents at the alpha-position. The parent of the class of benzoins.


A diphenylethane that is  1,2-dihydrostilbene substituted by a methyl group at position 1.


A diphenylethane that is 1,2-dihydrostilbene substituted by hydroxy groups at positions 4, 4', and 5 and a methoxy groups at positions 3 and 3'. It is isolated from Dendrobium ellipsophyllum and sensitizes lung cancer cells to anoikis.


dendrocandin E

A diphenylethane that is 1,2-dihydrostilbene substituted by hydroxy groups at positions 3, 3', 4 and 4' and a methoxy group at position 5. It is isolated from the stems of Dendrobium candidum and exhibits antioxidant activity.


A diphenylethane that is 1,2-dihydrostilbene substituted by hydroxy groups at positions 3, 3' and 5.


benzoins

An aromatic ketone containing a benzoin (2-hydroxy-1,2-diphenylethanone) skeleton.


dendrocandin D

A diphenylethane that is 1,2-dihydrostilbene substituted by hydroxy groups at positions 3, 4 and 4', a methoxy group at position 5 and an ethoxy group at alpha-position (the S stereoisomer). It is isolated from the stems of Dendrobium candidum and exhibits antioxidant activity.


dendrocandin C

A diphenylethane that is 1,2-dihydrostilbene substituted by hydroxy groups at positions 3, 4 and 4' and methoxy groups at C-5 and alpha-position respectively (the S stereoisomer). It is isolated from the stems of Dendrobium candidum and exhibits antioxidant activity.


name: HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 6

description: A lipid transport disorder characterized by extremely elevated levels of high density lipoprotein cholesterol (HDL C; HDLC). It is caused by heterozygous mutations in the SCARB1 gene that result in decreased transport of HCL C into the liver by scavenger receptor class B member 1.


A member of the class of pterocarpans that is (6aS,11aS)-3,6a,9-trihydroxypterocarpan in which the hydrogen atom at position 2 is substituted by a 3-methylbut-2-en-1-yl group.


Liver Partial Response GvHD

description: A decrease by 50% for ALT, alkaline phosphatase, and total bilirubin.


aflatoxin B2

An aflatoxin having a hexahydrocyclopenta[c]furo[3',2':4,5]furo[2,3-h]chromene skeleton with oxygen functionality at positions 1, 4 and 11.


hederacine B

An alkaloid isolated from Glechoma hederaceae.


name: 2-hydroxy-2-phenylacetic acid (1,2,6,6-tetramethyl-3-piperidinyl) ester


D-tagatose

The D-enantiomer of tagatose.


TAGATOSE

The straight-chain keto form of D-tagatose.


alpha-D-tagatopyranose

A D-tagatopyranose with an alpha-configuration at the anomeric center.


D-tagatopyranose

The pyranose form of D-tagatose.


beta-D-tagatofuranose

A D-tagatofuranose with a beta-configuration at the anomeric center.


alpha-D-tagatofuranose

A D-tagatofuranose with an alpha-configuration at the anomeric center.


D-tagatofuranose

The furanose form of D-tagatose.


beta-D-tagatopyranose

A D-tagatopyranose with a beta-configuration at the anomeric center.


name: Grade 3 Upper Extremity Vein Injury, CTCAE


carbonate ester

Any carbonate that is carbonic acid in which the hydrogens have been replaced by organyl groups.


(R)-tolpyralate

A 1-({1-ethyl-4-[3-(2-methoxyethoxy)-2-methyl-4-(methylsulfonyl)benzoyl]-1H-pyrazol-5-yl}oxy)ethyl methyl carbonate that has R-configuration.


(S)-tolpyralate

A 1-({1-ethyl-4-[3-(2-methoxyethoxy)-2-methyl-4-(methylsulfonyl)benzoyl]-1H-pyrazol-5-yl}oxy)ethyl methyl carbonate that has S-configuration.


A benzoylpyrazole that is 1H-pyrazole substituted by an ethyl, 3-(2-methoxyethoxy)-2-methyl-4-(methylsulfonyl)benzoyl, and 1-[(methoxycarbonyl)oxy]ethoxy groups at positions 1, 4 and 5, respectively.


dimethyl carbonate

A carbonate ester that is carbonic acid in which both hydrogens are replaced by methyl groups. A flammable, colourless liquid (m.p. 2-4degreeC, b.p. 90degreeC) with a characterstic ester-like odour, it is used as a 'green' methylating agent and as a solvent.


azilsartan medoxomil

A carboxylic ester obtained by formal condensation of the carboxy group of azilsartan with the hydroxy group of 4-(hydroxymethyl)-5-methyl-1,3-dioxol-2-one. A prodrug for azilsartan, it is used for treatment of hypertension.


SPIROTETRAMAT

An azaspiro compound that is methoxycyclohexane which is fused at position 4 to the 5-position of a 1,5-dihydro-2H-pyrrol-2-one that is substituted at positions 3 and 4 by 2,5-dimethylphenyl and (ethoxycarbonyl)oxy groups, respectively (the cis isomer). It is a proinsecticide (via hydrolysis of the ethyl carbonate group to give the corresponding 4-hydroxypyrrol-2-one, "spirotetramat-enol") and is used for the control of a wide range of sucking insects on fruit and potato crops.


(Z)-hex-3-en-1-yl methyl carbonate

A carbonate ester that is dimethyl carbonate in which one of the methyl groups has been replaced by a (Z)-hex-3-en-1-yl group. It has a floral scent and is used in the production of fruit or vegetable-like flavour additives.


diphenyl carbonate

A carbonate ester that is the diphenyl ester of carbonic acid.


methyl 4-nitrobenzyl carbonate

A carbonate ester that is dimethyl carbonate in which one of the methyl groups has been replaced by a 4-nitrobenzyl group.


spiropidion

An azaspiro compound that is 1-methoxypiperidine which is fused at position 4 to the 5-position of a 1,5-dihydro-2H-pyrrol-2-one that is substituted at positions 1, 3 and 4 by methyl, 4-chloro-2,6-dimethylphenyl and (ethoxycarbonyl)oxy groups, respectively. It is a proinsecticide developed by Syngenta and used to protect a wide range of crops from some of the most damaging, difficult to control sucking pests such as aphids, whiteflies, Pysllids, armoured scales, soft scales, spider mites, rust mites, and red mites including California red scale, green peach aphid (Myzus persicae), tobacco whitefly etc.


A carbonate ester resulting from the formal condensation of the hydroxy group of 5-(undeca-3,5,7-trien-1-yl)furan-2-ol with one of the hydroxy groups of carbonic acid. A metabolite of the endophytic fungus Emericellasp. XL029. The configuration of the double bonds of the undecatrienyl group is not stated.


spirobudifen

An oxaspiro compound that is 1-oxaspiro[4.5]dec-3-en-2-one substituted by 2,4-dichlorophenyl and (butoxycarbonyl)oxy groups at positions 3 and 4, respectively. It is an acaricide from Zhejiang Udragon Bioscience.


ampiroxicam

A benzothiazine that is the 1-[(ethoxycarbonyl)oxy]ethyl ether of piroxicam. A prodrug for piroxicam, it is used for the relief of pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis.


name: Grade 4 Sinusoidal Obstruction Syndrome, CTCAE

description: Life-threatening consequences (e.g., ventilatory support, dialysis, plasmapheresis, peritoneal drainage)


A 1-methyl-4-pyridone-5-carboxamide with 2 deuterium atoms replacing 2 hydrogen atoms.


A member of the class of 4-pyridones that is 4-pyridone substituted with a carboxamide group at C-3 and a methyl group at N-1.


(S)-salmeterol

2-(Hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol in which the stereocentre has S configuration.


salmeterol

A phenol having a hydroxymethyl group at C-2 and a 1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl group at C-4; derivative of phenylethanolamine.


(R)-salmeterol

2-(Hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol in which the stereocentre has R configuration.


name: Flow Reduced in Coronary Microcirculation

description: A finding of decreased blood flow in the microcirculation of the heart.


name: tris-L-cysteinyl L-cysteine persulfido L-glutamato L-histidino L-serinyl nickel triiron disulfide trioxide


Refractory Neuroblastoma

description: A neuroblastoma that does not respond to treatment.


methylcytidine

Any member of the class of cytidines that is cytidine substituted by at least one methyl group.


lysidine monophosphate

A pyrimidine ribonucleoside 5'-monophosphate that is CMP in which the 2-keto group on the cytosine ring is replaced by an epsilon-L-lysyl residue.


lysidine

Cytidine in which the 2-keto group on the cytosine ring is substituted by an epsilon-Llysyl residue.


Cytidine in which one of the exocyclic amino hydrogens is substituted by an acetyl group.


A member of the class of cytidines that is a metabolite of the drug capecitabine.


isocytidines

Any member of the class of pyrimidine ribonucleosides in which the pyrimidine moiety consists of 2-amino-4-hydroxypyrimidine or its derivatives.


agmatidine

Cytidine in which the 2-keto group on the cytosine ring is substituted by the amino group of agmatine.


name: Reactive Hyperplasia of the Retinal Pigment Epithelium

description: A reactive, non-neoplastic hyperplasia of the retinal pigment epithelium.


Grade 1 Rectal Ulcer, CTCAE

description: Asymptomatic; clinical or diagnostic observations only; intervention not indicated


name: Grade 3 Neuroendocrine ACTH Deficiency, CTCAE


Glu-Glu-Leu

A tripeptide composed of two L-glutamic acid residues and an L-leucine residue joined in sequence by peptide linkages.


CPK Increased, CTCAE

description: A finding based on laboratory test results that indicate an increase in levels of creatine phosphokinase in a blood specimen.


Grade 4 CPK Increased, CTCAE

description: >10 x ULN


Grade 1 CPK Increased, CTCAE

description: >ULN-2.5 x ULN


Grade 2 CPK Increased, CTCAE

description: >2.5 x ULN-5 x ULN


22-hydroxydocosanoic acid

An omega-hydroxy-long-chain fatty acid obtained by monohydroxylation of the terminal methyl group of docosanoic acid.


phosphatidylethanolamine (P-18:0/18:3)

A phosphatidylethanolamine P-36:3 in which the 1-alkenyl group contains 18 carbons and no additional double bonds while the acyl group contains 18 carbons and 3 double bonds.


Grade 2 Ovarian Infection, CTCAE

description: Localized; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)


name: Grade 5 Cranial Nerve VI Neuropathy, CTCAE


name: Grade 2 Bone Infection with Unknown Absolute Neutrophil Count, CTCAE


name: Bone Infection with Unknown Absolute Neutrophil Count, CTCAE


name: Grade 3 Bone Infection with Unknown Absolute Neutrophil Count, CTCAE


name: Grade 4 Bone Infection with Unknown Absolute Neutrophil Count, CTCAE


name: Grade 5 Bone Infection with Unknown Absolute Neutrophil Count, CTCAE


Adenosarcoma pT1c TNM Finding v7

description: Tumor invades more than half of the myometrium. (from AJCC 7th Ed.)


(S)-Fasnall

An N-(1-benzylpyrrolidin-3-yl)-5,6-dimethylthieno[2,3-d]pyrimidin-4-amine in which the chiral centre has S configuration. Both enantiomers act as fatty acid synthase inhibitors, although the (S)-enantiomer was found to be more than 4 times as active as the (R)-enantiomer.


Iris Implantation Cyst

description: A cyst that arises from the iris and is lined by squamous epithelium.


clavaldehyde

An organic heterobicyclic compound that is clavulanic acid in which the allylic alcohol group has been oxidised to the corresponding aldehyde.


Grade 2 Neonatal Pneumothorax, AE

description: An adverse event in a newborn characterized by radiological evidence of pneumothorax; minor clinical signs; minor care change required (e.g. oxygen, increased monitoring).


name: Other Inflammatory Spondylopathies, Cervicothoracic Region

description: Evidence of other inflammatory spondylopathies in the cervicothoracic region not specified elsewhere.


carbohydroximic acid

A carboximidic acid having an OH or OR (R = organyl) group attached to the imide nitrogen.


Colorectal Cancer pT4b TNM Finding v7

description: Colorectal cancer with direct invasion or adherence to other organs or structures. (from AJCC 7th Ed.)


boron-10 atom

A stable isotope of boron with relative atomic mass 10.0129370, 19.9 atom percent natural abundance and nuclear spin 3+.


An (omega-1)-hydroxy fatty acid ascaroside that is ascr#24 in which the pro-R hydrogen that is beta to the carboxy group is replaced by a hydroxy group. It is a metabolite of the nematode Caenorhabditis elegans.


(omega-1)-hydroxy fatty acid ascaroside

A hydroxy fatty acid ascaroside derived from an (omega-1)-hydroxy fatty acid.


An (omega-1)-hydroxy fatty acid ascaroside that is ascr#36 in which the pro-R hydrogen that is beta to the carboxy group is replaced by a hydroxy group. It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (2E,6R)-6-hydroxyhept-2-enoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of  the nematode Caenorhabditis elegans.


A 4-O-(1H-indol-3-ylcarbonyl)ascaroside derived from (11R)-11-hydroxylauric acid.  It is a metabolite of the nematode Caenorhabditis elegans.


An ascarosyloxycarboxylic acid beta-D-glucopyranosyl ester resulting from the formal esterification of the carboxy group of ascr#20 with the anomeric hydroxy group of beta-D-glucopyranose. It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (2E,18R)-18-hydroxynonadec-2-enoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (7R)-7-hydroxyoctanoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.


An ascarosyloxycarboxylic acid beta-D-glucopyranosyl ester resulting from the formal esterification of the carboxy group of ascr#22 with the anomeric hydroxy group of beta-D-glucopyranose. It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside that is bhas#24 in which the hydroxy group at position 4 of the ascarylopyranose moiety has been has been converted to the corresponding 1H-indole-3-carboxylate ester. It is a metabolite of the nematode Caenorhabditis elegans.


A 4-O-(1H-indol-3-ylcarbonyl)ascaroside derived from (10R)-10-hydroxyundecanoic acid. It is a metabolite of the nematode Caenorhabditis elegans.


A 4-O-(1H-indol-3-ylcarbonyl)ascaroside derived from (2E,6R)-6-hydroxyhept-2-enoic acid. It is a metabolite of the nematode Caenorhabditis elegans.


A 4-O-(1H-indol-3-ylcarbonyl)ascaroside derived from (8R)-8-hydroxynonanoic acid. It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (10R)-10-hydroxyundecanoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by obtained by formal condensation of the alcoholic hydroxy group of (24R)-2-methylpentacosanoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.


An ascarosyloxycarboxylic acid beta-D-glucopyranosyl ester resulting from the formal esterification of the carboxy group of ascr#24 with the anomeric hydroxy group of beta-D-glucopyranose. It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside that is ascr#16 in which the pro-R hydrogen that is beta to the carboxy group is replaced by a hydroxy group. It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (8R)-8-hydroxynonanoic acid with ascarylopyranose (the alpha anomer). A metabolite of the nematode Caenorhabditis elegans, it is the direct biosynthetic precursor to ascr#3. It has also been detected in the sour paste nematode, Panagrellus redivivus.


An ascarosyloxycarboxylic acid beta-D-glucopyranosyl ester resulting from the formal esterification of the carboxy group of ascr#1 with the anomeric hydroxy group of beta-D-glucopyranose. It is a metabolite of the nematode Caenorhabditis elegans.


An ascarosyloxycarboxylic acid beta-D-glucopyranosyl ester resulting from the formal esterification of the carboxy group of ascr#10 with the anomeric hydroxy group of beta-D-glucopyranose. It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (13R)-13-hydroxymyristic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.


A 4-O-(1H-indol-3-ylcarbonyl)ascaroside that is icas#10 in which the pro-R hydrogen beta to the carboxy group is replaced by a hydroxy group.  It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (2E,12R)-12-hydroxytridec-2-enoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.


A 4-O-(1H-indol-3-ylcarbonyl)ascaroside that is icas#18 in which the pro-R hydrogen beta to the carboxy group is replaced by a hydroxy group. It is a metabolite of the nematode Caenorhabditis elegans.


A 4-O-(1H-indol-3-ylcarbonyl)ascaroside derived from (12R)-12-hydroxytridecanoic acid. It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (2E,11R)-11-hydroxydodec-2-enoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside that is bhas#26 in which the hydroxy group at position 4 of the ascarylopyranose moiety has been has been converted to the corresponding 1H-indole-3-carboxylate ester. It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (2E,17R)-17-hydroxyoctadec-2-enoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.


A 4-O-(1H-indol-3-ylcarbonyl)ascaroside derived from  (2E,8R)-8-hydroxynon-2-enoic acid. It is a metabolite of the nematode Caenorhabditis elegans.


A 4-O-(1H-indol-3-ylcarbonyl)ascaroside derived from (9R)-9-hydroxydecanoic acid. It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (2E,8R)-8-hydroxynon-2-enoic acid with ascarylopyranose (the alpha anomer). It is a major component of the dauer pheromone, used by the nematode Caenorhabditis elegans as a population-density signal to promote entry into an alternate larval stage, the nonfeeding and highly persistent dauer diapause, and also synergises with ascr#2, ascr#4, and ascr#8 in male attraction.


A 4-O-(1H-indol-3-ylcarbonyl)ascaroside derived from (2E,12R)-12-hydroxytridec-2-enoic acid. It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside that is ascr#32 in which the pro-R hydrogen that is beta to the carboxy group is replaced by a hydroxy group. It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (2E,20R)-20-hydroxyhenicos-2-enoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (12R)-12-hydroxytridecanoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside that is ascr#34 in which the pro-R hydrogen that is beta to the carboxy group is replaced by a hydroxy group. It is a metabolite of the nematode Caenorhabditis elegans.


An ascarosyloxycarboxylic acid beta-D-glucopyranosyl ester resulting from the formal esterification of the carboxy group of ascr#3 with the anomeric hydroxy group of beta-D-glucopyranose. It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (2E,14R)-14-hydroxypentadec-2-enoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.


A 4-O-(1H-indol-3-ylcarbonyl)ascaroside that is icas#20 in which the pro-R hydrogen beta to the carboxy group is replaced by a hydroxy group. It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside consisting of  ascarylopyranose linked glycosidically to the alcoholic hydroxy group of (3R)-3-hydroxybutanoic acid.


A 4-O-(1H-indol-3-ylcarbonyl)ascaroside derived from (2E,9R)-9-hydroxydec-2-enoic acid. It is a metabolite of the nematode Caenorhabditis elegans.


An ascarosyloxycarboxylic acid beta-D-glucopyranosyl ester resulting from the formal esterification of the carboxy group of ascr#16 with the anomeric hydroxy group of beta-D-glucopyranose. It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (19R)-19-hydroxyicosanoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.


A 4-O-(1H-indol-3-ylcarbonyl)ascaroside derived from (4R)-4-hydroxypentanoic acid. It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the (omega-1)-hydroxy group of (3R,21R)-3,21-dihydroxydocosanoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.


An ascarosyloxycarboxylic acid beta-D-glucopyranosyl ester resulting from the formal esterification of the carboxy group of ascr#26 with the anomeric hydroxy group of beta-D-glucopyranose. It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (2E,16R)-16-hydroxyheptadec-2-enoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (2E,19R)-19-hydroxyicos-2-enoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.


A 4-O-(1H-indol-3-ylcarbonyl)ascaroside derived from (2E,11R)-11-hydroxydodec-2-enoic acid. It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside that is ascr#22 in which the pro-R hydrogen that is beta to the carboxy group is replaced by a hydroxy group. It is a metabolite of the nematode Caenorhabditis elegans.


A 4-O-(p-hydroxybenzoyl)ascaroside derived from (8R)-8-hydroxynonanoic acid. It is a metabolite of the nematode Caenorhabditis elegans.


A 4-O-(1H-indol-3-ylcarbonyl)ascaroside derived from (7R)-7-hydroxyoctanoic acid. It is a metabolite of the nematode Caenorhabditis elegans.


A 4-O-(1H-indol-3-ylcarbonyl)ascaroside derived from (2E,10R)-10-hydroxyundec-2-enoic acid. It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (4R)-4-hydroxypentanoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematodes Caenorhabditis elegans and Pristionchus pacificus.


An (omega-1)-hydroxy fatty acid ascaroside that is ascr#38 in which the pro-R hydrogen that is beta to the carboxy group is replaced by a hydroxy group. It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside that is ascr#28 in which the pro-R hydrogen that is beta to the carboxy group is replaced by a hydroxy group. It is a metabolite of the nematode Caenorhabditis elegans.


A 4-O-(1H-indol-3-ylcarbonyl)ascaroside that is icas#22 in which the pro-R hydrogen beta to the carboxy group is replaced by a hydroxy group. It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (16R)-16-hydroxymargaric acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (18R)-18-hydroxynonadecanoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (2E,6R)-6-hydroxyhept-2-enoic acid with ascarylopyranose (the alpha anomer). A metabolite of the nematode Caenorhabditis elegans, it is weakly dauer inducing and a weak male-attractant.


An (omega-1)-hydroxy fatty acid ascaroside obtained by obtained by formal condensation of the alcoholic hydroxy group of (2E,24R)-2-methylpentacos-2-enoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (2E,15R)-15-hydroxyhexadec-2-enoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (20R)-20-hydroxyhenicosanoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside that is ascr#18 in which the pro-R hydrogen that is beta to the carboxy group is replaced by a hydroxy group. It is a metabolite of the nematode Caenorhabditis elegans as well as the sour paste nematode, Panagrellus redivivus.


A 4-O-(1H-indol-3-ylcarbonyl)ascaroside derived from (5R)-5-hydroxyhexanoic acid. It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside that is bhas#28 in which the hydroxy group at position 4 of the ascarylopyranose moiety has been has been converted to the corresponding 1H-indole-3-carboxylate ester. It is a metabolite of the nematode Caenorhabditis elegans.


DAUMONE

An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (6R)-6-hydroxyheptanoic acid with ascarylopyranose (the alpha anomer). It is a major component of the dauer pheromone, used by the nematode Caenorhabditis elegans as a population-density signal to promote entry into an alternate larval stage, the nonfeeding and highly persistent dauer diapause. It has also been found in Pristionchus pacificus and the sour paste nematode Panagrellus redivivus.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (14R)-14-hydroxypentadecanoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.


An ascarosyloxycarboxylic acid beta-D-glucopyranosyl ester resulting from the formal esterification of the carboxy group of ascr#18 with the anomeric hydroxy group of beta-D-glucopyranose. It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside that is ascr#20 in which the pro-R hydrogen that is beta to the carboxy group is replaced by a hydroxy group. It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (9R)-9-hydroxydecanoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (17R)-17-hydroxystearic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside that is ascr#26 in which the pro-R hydrogen that is beta to the carboxy group is replaced by a hydroxy group. It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (2E,9R)-9-hydroxydec-2-enoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside that is bhas#30 in which the hydroxy group at position 4 of the ascarylopyranose moiety has been has been converted to the corresponding 1H-indole-3-carboxylate ester. It is a metabolite of the nematode Caenorhabditis elegans.


A 4-O-(1H-indol-3-ylcarbonyl)ascaroside derived from (6R)-6-hydroxyheptanoic acid. It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (2E,10R)-10-hydroxyundec-2-enoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (2E,13R)-13-hydroxytetradec-2-enoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.


A 4-O-(p-hydroxybenzoyl)ascaroside derived from (2E,8R)-8-hydroxynon-2-enoic acid. It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (5R)-5-hydroxyhexanoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematodes Caenorhabditis elegans and Pristionchus pacificus.


A 4-O-(1H-indol-3-ylcarbonyl)ascaroside that is icas#16 in which the pro-R hydrogen beta to the carboxy group is replaced by a hydroxy group. It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside that is ascr#30 in which the pro-R hydrogen that is beta to the carboxy group is replaced by a hydroxy group. It is a metabolite of the nematode Caenorhabditis elegans.


An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (11R)-11-hydroxylauric acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.


A carboxamide resulting from the formal condensation of the carboxy group of ascr#7 with the amino group of 4-aminobenzoic acid. A metabolite of the nematode Caenorhabditis elegans, it is dauer inducing and strongly male attracting.


anaerobilin dizwitterion

An  iminium betaine resulting from a transfer of two protons from the carboxy groups to the imino groups of anaerobilin; major species at pH 7.3.


BUTYROLACTONE I

The prenylated form of butyrolactone II; major microspecies at pH 7.3


name: epilepsy, idiopathic generalized, susceptibility to, 6


ethyl N-acetylneuraminate

The carboxylic ester that is the ethyl ester of N-acetylneuraminic acid.


NIGRASIN F

An extended flavonoid that is the 2S*-diastereomer of nigrasin E. It has been isolated from the twigs of Morus nigra.


Ins-1-P-Cer B/B'

An inositol phosphoceramide in which either the acyl group is hydroxylated at position 2 or the ceramide base is hydroxylated at position 4.


beta-D-fructofuranose 6-phosphate

A D-fructofuranose 6-phosphate with a beta-configuration at the anomeric position.


D-fructofuranose 6-phosphate

The five-membered ring form of D-fructose 6-phosphate.


name: Hypertension secondary to other renal disorders

description: Evidence of hypertension secondary to other renal disorders.


IWG-MRT Myelofibrosis Partial Remission

description: Peripheral blood: Hemoglobin greater than or equal to 100 g/L and less than upper normal limit; neutrophil count greater than or equal to 1x10^9/L and less than upper normal limit; platelet count greater than or equal to 100x10^9/L and less than upper normal limit; less than 2 percent immature myeloid cells and Clinical: Resolution of disease symptoms; spleen and liver not palpable; no evidence of extramedullary hematopoiesis or Bone marrow: Age-adjusted normocellularity; less than 5 percent blasts; less than grade 1 myelofibrosis and peripheral blood: Hemoglobin greater than or equal to 85 but less than 100 g/L and less than upper normal limit; neutrophil count greater than 1x10^9/L and less than upper normal limit; platelet count greater than or equal to 50 but less than 100x10^9/L and less than upper normal limit; less than 2 percent immature myeloid cells and Clinical: Resolution of disease symptoms; spleen and liver not palpable; no evidence of extramedullary hematopoiesis(adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)


name: IWG-MRT Criteria for Treatment Response in Myelofibrosis

description: Criteria in inducing remission or improvement in myelofibrosis according to the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT).


IWG-MRT Myelofibrosis Anemia Response

description: Transfusion-independent patients: a greater than or equal to 20 g/L increase in hemoglobin level or for transfusion-dependent patients: becoming transfusion-independent (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)


name: IWG-MRT Myelofibrosis Molecular Remission

description: Molecular response evaluation must be analyzed in peripheral blood granulocytes and requires confirmation by repeat testing within 6 months window. Complete response: Eradication of a pre-existing abnormality. Partial response: greater than or equal to 50 percent decrease in allele burden (partial response applies only to patients with at least 20 percent mutant allele burden at baseline.) (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)


name: IWG-MRT Myelofibrosis Progressive Disease

description: Appearance of a new splenomegaly that is palpable at least 5 cm below the left costal margin or A greater than or equal to 100 percent increase in palpable distance, below left costal margin, for baseline splenomegaly of 5 to 10 cm or A 50 percent increase in palpable distance, below left costal margin, for baseline splenomegaly of greater than 10 cm or Leukemic transformation confirmed by a bone marrow blast count of greater than or equal to 20 percent or A peripheral blood blast content of greater than or equal to 20 percent associated with an absolute blast count of greater than or equal to 1x10^9/L that lasts for at least 2 weeks (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD, 22 AUGUST 2013 x VOLUME 122, NUMBER 8)


IWG-MRT Myelofibrosis Stable Disease

description: Belonging to none of the above listed response categories (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)


IWG-MRT Myelofibrosis Spleen Response

description: A baseline splenomegaly that is palpable at 5-10 cm below the left costal margin becomes not palpable or A baseline splenomegaly that is palpable at greater than 10 cm below the left costal margin decreases by greater than or equal to 50 percent. A baseline splenomegaly that is palpable at less than 5 cm below the left costal margin is not eligible for spleen response. A spleen response requires confirmation by MRI or computed tomography showing greater than or equal to 35 percent spleen volume reduction. (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)


IWG-MRT Myelofibrosis Relapse

description: No longer meeting criteria for at least clinical improvement after achieving complete response partial response or clinical improvement or loss of anemia response persisting for at least 1 month or loss of spleen response persisting for at least 1 month (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)


name: IWG-MRT Myelofibrosis Clinical Improvement

description: The achievement of anemia spleen or symptoms response without progressive disease or increase in severity of anemia thrombocytopenia or neutropenia (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)


name: IWG-MRT Myelofibrosis Complete Remission

description: Bone marrow: Age-adjusted normocellularity; less than 5 percent blasts; less than or equal to grade 1 myelofibrosis and Peripheral blood: Hemoglobin greater than or equal to 100 g/L and less than upper normal limit; neutrophil count greater than or equal 1x10^9/L and less than upper normal limit; Platelet count greater or equal to 100x10^9/L and less than upper normal limit; less than 2 percent immature myeloid cells and Clinical: Resolution of disease symptoms; spleen and liver not palpable; no evidence of extramedullary hematopoiesis (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)


name: IWG-MRT Myelofibrosis Cytogenetic Remission

description: At least 10 metaphases must be analyzed for cytogenetic response evaluation and requires confirmation by repeat testing within 6 months window. Complete response: eradication of a preexisting abnormality. Partial response: greater than or equal to 50 percent reduction in abnormal metaphases. (partial response applies only to patients with at least ten abnormal metaphases at baseline) (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)


IWG-MRT Myelofibrosis Symptom Response

description: A greater than or equal to 50 percent reduction in the myeloproliferative neoplasm symptom assessment form total symptom score (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)


name: Grade 2 Bladder Infection with Unknown Absolute Neutrophil Count, CTCAE


Excessive Bleeding

description: Abnormally heavy or prolonged loss of blood.


(R)-myclobutanil

A 2-(4-chlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)hexanenitrile that has R configuration.


beta-aminoarteether

An artemisinin derivative in which the lactone of (+)-artemisinin has been converted into the corresponding lactol 2-aminoethyl ether [beta (S) configuration at the new stereocentre].


A sphingomyelin 41:2 obtained by formal condensation of the carboxy group of tricosanoic acid with the amino group of any sphingadienine-1-phosphocholine.


N-triacontanoylsphinganine

A dihydroceramide in which the ceramide N-acyl group is specified as tricontanoyl.


Non-toxic multinodular goiter

description: A multinodular goiter that is not associated with changes in thyroid function or malignancy.


Multinodular Endemic Goiter

description: A multinodular goiter caused by inadequate iodine intake.


name: Cervical and Lumbosacral Spinal Cord Ependymal Tumor

description: A finding indicating the presence of an ependymal tumor in the cervical and lumbosacral regions of spinal cord.


N-formyl-L-tyrosine

An N-formyl amino acid that is L-tyrosine in which one of the hydrogens of the amino group has been replaced by a formyl group.


N-benzoyl-L-tyrosine

An N-acyl-L-tyrosine that is L-tyrosine in which one of the hydrogens of the amino group has been replaced by a benzoyl group.


N-Acetyltyrosine

An N-acetyltyrosine in which the chiral centre has L configuration.


N-sulfotyrosine

An N-acyl-L-tyrosine obtained by replaceing one of the amino hydrogens with a sulfo group.


2-phenylethyl pentanoate

A fatty acid ester obtained by the formal condensation of 2-phenylethanol with  valeric acid.


PHENETHYL ISOCYANATE

An isocyanate having a 2-phenylethyl group attached to the nitrogen.


thiosulfonate ester

An organosulfur compound with the formula RSO2SR.


An aminooxyl that is pyrroline substituted by an oxidanediyl group at position 1, by methyl groups at positions 2, 2, 5 and 5, and by a [(methylsulfonyl)sulfanyl]methyl group at position 3. It is a highly reactive thiol-specific spin label.


Tyr-Gly-Gly

A tripeptide composed of one L-tyrosine and two glycine residues joined in sequence.


Adult Leiomyosarcoma

description: An aggressive malignant smooth muscle neoplasm, occurring in adults.  It is characterized by a proliferation of neoplastic spindle cells.


Penile Leiomyosarcoma

description: A leiomyosarcoma that occurs in the penis.


Unresectable Leiomyosarcoma

description: A leiomyosarcoma which is not amenable to surgical resection.


Dedifferentiated Leiomyosarcoma

description: A pleomorphic leiomyosarcoma that lacks immunohistochemical staining for myogenic markers in the pleomorphic areas.


name: Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8

description: Stage IVB includes: Any T, Any N, M1. M1: M1: Distant metastasis (excluding adnexa, pelvic, and abdominal tissues). (from AJCC 8th Ed.)


Pancreatic Leiomyosarcoma

description: A rare leiomyosarcoma that arises from the pancreas.


Head and Neck Leiomyosarcoma

description: A malignant neoplasm with smooth muscle differentiation that arises from the head and neck. The most frequently affected sites are the subcutaneous and deep neck soft tissues.


name: Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8

description: Stage IIIA includes: T3a, N0, M0. T3a: Uterine corpus leiomyosarcoma with tumor infiltrating abdominal tissues at one site. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)


name: Stage I Uterine Corpus Leiomyosarcoma AJCC v8

description: Stage I includes: T1, N0, M0. T1: Uterine corpus leiomyosarcoma with tumor limited to the uterus. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)


name: Stage IV Uterine Corpus Leiomyosarcoma AJCC v8

description: Stage IV includes: IVA: T4, Any N, M0; IVB: Any T, Any N, M1. T4: Uterine corpus leiomyosarcoma with tumor invading bladder or rectum. M0: No distant metastasis. M1: Distant metastasis (excluding adnexa, pelvic, and abdominal tissues). (from AJCC 8th Ed.)


Primary leiomyosarcoma

description: Leiomyosarcoma that is confined to a specific site without evidence of spread to other anatomic sites.


EBV-Related Leiomyosarcoma

description: Leiomyosarcoma that is caused by Epstein-Barr virus infection.


Inferior Vena Cava Leiomyosarcoma

description: An aggressive malignant smooth muscle neoplasm, arising from the inferior vena cava.  It is characterized by a proliferation of neoplastic spindle cells.


Metastatic leiomyosarcoma

description: A leiomyosarcoma that has spread to other anatomic sites.


leiomyosarcoma of appendix

description: A rare leiomyosarcoma that arises from the appendiceal wall.


Unresectable Soft Tissue Leiomyosarcoma

description: A soft tissue leiomyosarcoma that is not amenable to surgical resection.


name: Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8

description: Stage IVA includes: T4, Any N, M0. T4: Uterine corpus leiomyosarcoma with tumor invading bladder or rectum. M0: No distant metastasis. (from AJCC 8th Ed.)


Conjunctival Leiomyosarcoma

description: A leiomyosarcoma that arises from the conjunctiva.


Seminal Vesicle Leiomyosarcoma

description: A rare leiomyosarcoma that affects the seminal vesicle.


name: Stage IB Uterine Corpus Leiomyosarcoma AJCC v8

description: Stage IB includes: T1b, N0, M0. T1b: Uterine corpus leiomyosarcoma with tumor limited to the uterus, measuring more than 5 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)


Pleomorphic leiomyosarcoma

description: A leiomyosarcoma characterized by the presence of poorly differentiated areas with pleomorphic appearance, in addition to areas with typical morphologic features.


Refractory Leiomyosarcoma

description: Leiomyosarcoma that does not respond to treatment.


Leiomyosarcoma of Vessels

description: An aggressive malignant smooth muscle neoplasm, arising from the walls of the vascular system.  It is characterized by a proliferation of neoplastic spindle cells.


leiomyosarcoma of bladder

description: A leiomyosarcoma that arises from the bladder. It is the most common type of bladder sarcoma in adults.


Broad Ligament Leiomyosarcoma

description: A rare leiomyosarcoma that arises from the broad ligament.


name: Unresectable Uterine Corpus Leiomyosarcoma

description: Uterine corpus leiomyosarcoma that is not amenable to surgical resection.


Advanced Soft Tissue Leiomyosarcoma

description: A soft tissue leiomyosarcoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


name: Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8

description: Stage IIIB includes: T3b, N0, M0. T3b: Uterine corpus leiomyosarcoma with tumor infiltrating abdominal tissues at more than one site. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)


name: Uterine Corpus Leiomyosarcoma by AJCC v8 Stage

description: A term that refers to the staging of uterine corpus leiomyosarcoma according to the American Joint Committee on Cancer, 8th edition.


name: Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8

description: Stage IIIC includes: T1-3, N1, M0. T1: Uterine corpus leiomyosarcoma with tumor limited to the uterus. T2: Uterine corpus leiomyosarcoma with tumor extending beyond the uterus, within the pelvis. T3: Uterine corpus leiomyosarcoma with tumor infiltrating abdominal tissues. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)


Childhood Leiomyosarcoma

description: An aggressive malignant smooth muscle neoplasm, occurring in children.  It is characterized by a proliferation of neoplastic spindle cells.


Leiomyosarcoma recurrent

description: The reemergence of leiomyosarcoma after a period of remission


name: Locally Recurrent Uterine Corpus Leiomyosarcoma

description: The reemergence of uterine corpus leiomyosarcoma after a period of remission, at or adjacent to the site of the original tumor.


name: Stage III Uterine Corpus Leiomyosarcoma AJCC v8

description: Stage III includes: IIIA: T3a, N0, M0; IIIB: T3b, N0, M0; IIIC: T1-3, N1, M0. T1: Uterine corpus leiomyosarcoma with tumor limited to the uterus. T2: Uterine corpus leiomyosarcoma with tumor extending beyond the uterus, within the pelvis. T3: Uterine corpus leiomyosarcoma with tumor infiltrating abdominal tissues. T3a: Uterine corpus leiomyosarcoma with tumor infiltrating abdominal tissues at one site. T3b: Uterine corpus leiomyosarcoma with tumor infiltrating abdominal tissues at more than one site. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)


Thyroid Gland Leiomyosarcoma

description: A leiomyosarcoma that arises from the thyroid gland.


name: Metastatic Uterine Corpus Leiomyosarcoma

description: Uterine corpus leiomyosarcoma that has spread from its original site of growth to another anatomic site.


name: Locally Advanced Uterine Corpus Leiomyosarcoma

description: Uterine corpus leiomyosarcoma that has spread to nearby tissues or lymph nodes.


Colorectal Leiomyosarcoma

description: An aggressive malignant smooth muscle neoplasm that arises from the colon or rectum.  It is characterized by a proliferation of neoplastic spindle cells.


Metastatic Soft Tissue Leiomyosarcoma

description: A soft tissue leiomyosarcoma that has spread from the original site of growth to another anatomic site.


Sinonasal Leiomyosarcoma

description: A leiomyosarcoma that arises from the nasal cavity and paranasal sinuses.


Well Differentiated Leiomyosarcoma

description: Grade I malignant smooth muscle neoplasm.  It is characterized by a proliferation of neoplastic spindle cells.


name: Stage IA Uterine Corpus Leiomyosarcoma AJCC v8

description: Stage IA includes: T1a, N0, M0. T1a: Uterine corpus leiomyosarcoma with tumor limited to the uterus, measuring 5 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)


Digestive System Leiomyosarcoma

description: A leiomyosarcoma arising from an anatomic site in the digestive system.


Resectable Leiomyosarcoma

description: Leiomyosarcoma that is amenable to surgical resection.


Advanced Leiomyosarcoma

description: A leiomyosarcoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


name: Locally Advanced Soft Tissue Leiomyosarcoma

description: Soft tissue leiomyosarcoma that has spread to nearby tissues or lymph nodes.


Locally Advanced Leiomyosarcoma

description: A leiomyosarcoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Leiomyosarcoma of Deep Soft Tissue

description: A rare leiomyosarcoma that arises from the deep soft tissue in the retroperitoneum or abdominal cavity.


name: Lesion with Diameter at Least 11 mm and at Most 20 mm

description: A semi-quantitative finding indicating that the largest diameter for a lesion was at least 11 mm and at most 20 mm.


(R)-crotonylcarnitine

A O-butenoyl-L-carnitine  in which the acyl group is specified as crotonyl.


An O-acyl-L-carnitine obtained by formal condensation of the carboxy group of any 2-enoic acid with the hydroxy group of L-carnitine.


name: Grade 4 Skin Infection with Normal Absolute Neutrophil Count or Grade 1 or 2 Neutrophils, CTCAE


Grade 2 Aortic Injury, CTCAE

description: Operative intervention not indicated


The 6-O-methyl derivative of norlaudanosoline.


name: Refractory Malignant Soft Tissue Neoplasm

description: Malignant soft tissue neoplasm that is resistant to treatment.


Refractory Extrarenal Rhabdoid Tumor

description: Extrarenal rhabdoid tumor that is  resistant to treatment.


Hepatitis B Surface Antibody Negative

description: An indication that antibodies that recognize a hepatitis B virus surface protein have not been detected in a sample.


A member of the class of aminopyrimidines that is pyrimidine-2,4-diamine substituted at positions N-2 and N-4 by 3-methoxy-4-(morpholin-4-yl)phenyl and quinolin-3-yl groups respectively.


Digestive System Solitary Fibrous Tumor

description: A solitary fibrous tumor arising from an anatomic site in the digestive system, including the esophagus, gallbladder, liver, pancreas, small bowel mesentery, and the serosal surfaces of the stomach and colon.


Skin tumor of smooth muscle origin

description: A smooth muscle neoplasm occurring in the skin.


Pilar Leiomyoma

description: A cutaneous leiomyoma arising from the arrector pili muscle.


An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of oscr#9


name: Monoplegia of Upper Limb following Non-Traumatic Intracerebral Hemorrhage Affecting Right Dominant Side

description: Evidence of monoplegia of upper limb following non-traumatic intracerebral hemorrhage affecting right dominant side.


PDGFR Positive

description: Indicates that the expression of a member of the PDGFR family has been detected in a sample.


PDGFRB Positive

description: Indicates that PDGFRB expression has been detected in a sample.


PDGFRA Positive

description: Indicates that PDGFRA expression has been detected in a sample.